48,731
edits
Line 122: | Line 122: | ||
**CK20 may be negative. | **CK20 may be negative. | ||
UCC vs. Prostate | UCC vs. Prostate: | ||
*UCC: p63+, PSA-, PSAP-, CK7+, CK20+. | *UCC: p63+, PSA-, PSAP-, CK7+, CK20+. | ||
*Prostate: p63-, PSA+, PSAP+, CK7-, CK20-. | *Prostate: p63-, PSA+, PSAP+, CK7-, CK20-. | ||
UCC vs. RCC: | |||
*UCC: p63+.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | |||
</ref> | |||
==UCC (papillary lesions)== | ==UCC (papillary lesions)== |
edits